146 related articles for article (PubMed ID: 9507531)
1. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.
Bridewell DJ; Finlay GJ; Baguley BC
Oncol Res; 1997; 9(10):535-42. PubMed ID: 9507531
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
[TBL] [Abstract][Full Text] [Related]
3. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.
Jensen PB; Jensen PS; Demant EJ; Friche E; Sørensen BS; Sehested M; Wassermann K; Vindeløv L; Westergaard O; Hansen HH
Cancer Res; 1991 Oct; 51(19):5093-9. PubMed ID: 1655244
[TBL] [Abstract][Full Text] [Related]
4. Aclacinomycin A stabilizes topoisomerase I covalent complexes.
Nitiss JL; Pourquier P; Pommier Y
Cancer Res; 1997 Oct; 57(20):4564-9. PubMed ID: 9377570
[TBL] [Abstract][Full Text] [Related]
5. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
6. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
7. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.
Wassermann K; Markovits J; Jaxel C; Capranico G; Kohn KW; Pommier Y
Mol Pharmacol; 1990 Jul; 38(1):38-45. PubMed ID: 2164630
[TBL] [Abstract][Full Text] [Related]
8. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor.
Hajji N; Mateos S; Pastor N; Domínguez I; Cortés F
Mutat Res; 2005 May; 583(1):26-35. PubMed ID: 15866463
[TBL] [Abstract][Full Text] [Related]
9. A novel use for the comet assay: detection of topoisomerase II inhibitors.
Salti GI; Das Gupta TK; Constantinou AI
Anticancer Res; 2000; 20(5A):3189-93. PubMed ID: 11062742
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
11. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I.
Sørensen BS; Jensen PB; Sehested M; Jensen PS; Kjeldsen E; Nielsen OF; Alsner J
Biochem Pharmacol; 1994 Jun; 47(11):2105-10. PubMed ID: 8010996
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Bridewell DJ; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells.
Solier S; Lansiaux A; Logette E; Wu J; Soret J; Tazi J; Bailly C; Desoche L; Solary E; Corcos L
Mol Cancer Res; 2004 Jan; 2(1):53-61. PubMed ID: 14757846
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.
Koceva-Chyła A; Jedrzejczak M; Skierski J; Kania K; Jóźwiak Z
Apoptosis; 2005 Dec; 10(6):1497-514. PubMed ID: 16215684
[TBL] [Abstract][Full Text] [Related]
15. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.
De Graff WG; Myers LS; Mitchell JB; Hahn SM
Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
[TBL] [Abstract][Full Text] [Related]
17. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.
Snapka RM; Gao H; Grabowski DR; Brill D; Chan KK; Li L; Li GC; Ganapathi R
Biochem Biophys Res Commun; 2001 Feb; 280(4):1155-60. PubMed ID: 11162648
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide.
Mizutani H; Tada-Oikawa S; Hiraku Y; Kojima M; Kawanishi S
Life Sci; 2005 Feb; 76(13):1439-53. PubMed ID: 15680309
[TBL] [Abstract][Full Text] [Related]
20. Lycobetaine acts as a selective topoisomerase II beta poison and inhibits the growth of human tumour cells.
Barthelmes HU; Niederberger E; Roth T; Schulte K; Tang WC; Boege F; Fiebig HH; Eisenbrand G; Marko D
Br J Cancer; 2001 Nov; 85(10):1585-91. PubMed ID: 11720449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
